Cargando…
Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure
BACKGROUND: Recent studies indicated that sodium glucose cotransporter (SGLT)2 inhibition increases levels of ketone bodies in the blood in patients with type 1 and 2 diabetes. Other studies suggested that in patients with chronic heart failure (CHF), increased myocardial oxygen demand can be provid...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8579532/ https://www.ncbi.nlm.nih.gov/pubmed/34753480 http://dx.doi.org/10.1186/s12933-021-01410-7 |
_version_ | 1784596444989095936 |
---|---|
author | Pietschner, R. Kolwelter, J. Bosch, A. Striepe, K. Jung, S. Kannenkeril, D. Ott, C. Schiffer, M. Achenbach, S. Schmieder, R. E. |
author_facet | Pietschner, R. Kolwelter, J. Bosch, A. Striepe, K. Jung, S. Kannenkeril, D. Ott, C. Schiffer, M. Achenbach, S. Schmieder, R. E. |
author_sort | Pietschner, R. |
collection | PubMed |
description | BACKGROUND: Recent studies indicated that sodium glucose cotransporter (SGLT)2 inhibition increases levels of ketone bodies in the blood in patients with type 1 and 2 diabetes. Other studies suggested that in patients with chronic heart failure (CHF), increased myocardial oxygen demand can be provided by ketone bodies as a fuel substrate. Experimental studies reported that ketone bodies, specifically beta-hydroxybutyrate (β-OHB) may increase blood pressure (BP) by impairing endothelium-dependant relaxation, thereby leading to increased vascular stiffness. In our study we assessed whether the SGLT 2 inhibition with empagliflozin increases ketone bodies in patients with stable CHF and whether such an increase impairs BP and vascular function. METHODS: In a prospective, double blind, placebo controlled, parallel-group single centre study 75 patients with CHF (left ventricular ejection fraction 39.0 ± 8.2%) were randomised (2:1) to the SGLT-2 inhibitor empagliflozin 10 mg orally once daily or to placebo, 72 patients completed the study. After a run-in phase we evaluated at baseline BP by 24 h ambulatory blood pressure (ABP) monitoring, vascular stiffness parameters by the SphygmoCor system (AtCor Medical, Sydney, NSW, Australia) and fasting metabolic parameters, including β-OHB by an enzymatic assay (Beckman Coulter DxC 700 AU). The same measurements were repeated 12 weeks after treatment. In 19 of the 72 patients serum levels of β-OHB were beneath the lower border of our assay (< 0.05 mmol/l) therefore being excluded from the subsequent analysis. RESULTS: In patients with stable CHF, treatment with empagliflozin (n = 36) was followed by an increase of β-OHB by 33.39% (p = 0.017), reduction in 24 h systolic (p = 0.038) and diastolic (p = 0.085) ABP, weight loss (p = 0.003) and decrease of central systolic BP (p = 0.008) and central pulse pressure (p = 0.008). The increase in β-OHB was related to an attenuated decrease of empagliflozin-induced 24 h systolic (r = 0.321, p = 0.069) and diastolic (r = 0.516, p = 0.002) ABP and less reduction of central systolic BP (r = 0.470, p = 0.009) and central pulse pressure (r = 0.391, p = 0.033). No significant changes were seen in any of these parameters after 12 weeks of treatment in the placebo group (n = 17). CONCLUSION: In patients with stable CHF ketone bodies as assessed by β-OHB increased after treatment with empagliflozin. This increase led to an attenuation of the beneficial effects of empagliflozin on BP and vascular parameters. Trial registration The study was registered at http://www.clinicaltrials.gov (NCT03128528). |
format | Online Article Text |
id | pubmed-8579532 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-85795322021-11-10 Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure Pietschner, R. Kolwelter, J. Bosch, A. Striepe, K. Jung, S. Kannenkeril, D. Ott, C. Schiffer, M. Achenbach, S. Schmieder, R. E. Cardiovasc Diabetol Original Investigation BACKGROUND: Recent studies indicated that sodium glucose cotransporter (SGLT)2 inhibition increases levels of ketone bodies in the blood in patients with type 1 and 2 diabetes. Other studies suggested that in patients with chronic heart failure (CHF), increased myocardial oxygen demand can be provided by ketone bodies as a fuel substrate. Experimental studies reported that ketone bodies, specifically beta-hydroxybutyrate (β-OHB) may increase blood pressure (BP) by impairing endothelium-dependant relaxation, thereby leading to increased vascular stiffness. In our study we assessed whether the SGLT 2 inhibition with empagliflozin increases ketone bodies in patients with stable CHF and whether such an increase impairs BP and vascular function. METHODS: In a prospective, double blind, placebo controlled, parallel-group single centre study 75 patients with CHF (left ventricular ejection fraction 39.0 ± 8.2%) were randomised (2:1) to the SGLT-2 inhibitor empagliflozin 10 mg orally once daily or to placebo, 72 patients completed the study. After a run-in phase we evaluated at baseline BP by 24 h ambulatory blood pressure (ABP) monitoring, vascular stiffness parameters by the SphygmoCor system (AtCor Medical, Sydney, NSW, Australia) and fasting metabolic parameters, including β-OHB by an enzymatic assay (Beckman Coulter DxC 700 AU). The same measurements were repeated 12 weeks after treatment. In 19 of the 72 patients serum levels of β-OHB were beneath the lower border of our assay (< 0.05 mmol/l) therefore being excluded from the subsequent analysis. RESULTS: In patients with stable CHF, treatment with empagliflozin (n = 36) was followed by an increase of β-OHB by 33.39% (p = 0.017), reduction in 24 h systolic (p = 0.038) and diastolic (p = 0.085) ABP, weight loss (p = 0.003) and decrease of central systolic BP (p = 0.008) and central pulse pressure (p = 0.008). The increase in β-OHB was related to an attenuated decrease of empagliflozin-induced 24 h systolic (r = 0.321, p = 0.069) and diastolic (r = 0.516, p = 0.002) ABP and less reduction of central systolic BP (r = 0.470, p = 0.009) and central pulse pressure (r = 0.391, p = 0.033). No significant changes were seen in any of these parameters after 12 weeks of treatment in the placebo group (n = 17). CONCLUSION: In patients with stable CHF ketone bodies as assessed by β-OHB increased after treatment with empagliflozin. This increase led to an attenuation of the beneficial effects of empagliflozin on BP and vascular parameters. Trial registration The study was registered at http://www.clinicaltrials.gov (NCT03128528). BioMed Central 2021-11-09 /pmc/articles/PMC8579532/ /pubmed/34753480 http://dx.doi.org/10.1186/s12933-021-01410-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Original Investigation Pietschner, R. Kolwelter, J. Bosch, A. Striepe, K. Jung, S. Kannenkeril, D. Ott, C. Schiffer, M. Achenbach, S. Schmieder, R. E. Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure |
title | Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure |
title_full | Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure |
title_fullStr | Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure |
title_full_unstemmed | Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure |
title_short | Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure |
title_sort | effect of empagliflozin on ketone bodies in patients with stable chronic heart failure |
topic | Original Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8579532/ https://www.ncbi.nlm.nih.gov/pubmed/34753480 http://dx.doi.org/10.1186/s12933-021-01410-7 |
work_keys_str_mv | AT pietschnerr effectofempagliflozinonketonebodiesinpatientswithstablechronicheartfailure AT kolwelterj effectofempagliflozinonketonebodiesinpatientswithstablechronicheartfailure AT boscha effectofempagliflozinonketonebodiesinpatientswithstablechronicheartfailure AT striepek effectofempagliflozinonketonebodiesinpatientswithstablechronicheartfailure AT jungs effectofempagliflozinonketonebodiesinpatientswithstablechronicheartfailure AT kannenkerild effectofempagliflozinonketonebodiesinpatientswithstablechronicheartfailure AT ottc effectofempagliflozinonketonebodiesinpatientswithstablechronicheartfailure AT schifferm effectofempagliflozinonketonebodiesinpatientswithstablechronicheartfailure AT achenbachs effectofempagliflozinonketonebodiesinpatientswithstablechronicheartfailure AT schmiederre effectofempagliflozinonketonebodiesinpatientswithstablechronicheartfailure |